Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | May 18, 2022 | clinicaltrials |
| NCT02704156 | SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer | completed | Phase 2 | 170 | Changhai HospitalOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02080260 | A Study of Regorafenib in Advanced Pancreatic Cancer Patients | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04258150 | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer(TRIPPLE-R) | terminated | Phase 2 | 26 | Herlev HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05298020 | Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 51 | Zhejiang UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01360593 | Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma | completed | Phase 2 | 35 | David A. Clump, MD, PhDOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02131493 | S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer | completed | Phase 2 | 80 | Zhejiang UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT00617708 | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 134 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT05168527 | The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT04790695 | Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab | completed | Phase 2 | 1 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05185869 | SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer | unknown | Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT04070313 | A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan | terminated | Phase 2 | 36 | TTY BiopharmINDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05138159 | A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT01303172 | A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer | completed | Phase 2 | 110 | Immodulon Therapeutics LtdINDUSTRY | 5 | Nov 10, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05100329 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer | unknown | Phase 2 | 38 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Oct 29, 2021 | clinicaltrials |
| NCT03023722 | Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer | completed | Phase 2 | 18 | Yale UniversityOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04089150 | MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease(MASTERPLAN) | unknown | Phase 2 | 120 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | Oct 22, 2021 | clinicaltrials |
| NCT03599362 | Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer | terminated | Phase 2 | 7 | NYU Langone HealthOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT00112580 | MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 27 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 27, 2021 | clinicaltrials |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | completed | Phase 2 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 20, 2021 | clinicaltrials |
| NCT00010166 | Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas | completed | Phase 2 | 26 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00025168 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00597129 | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | completed | Phase 1 / Phase 2 | 21 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02305186 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer(UVA-PC-PD101) | unknown | Phase 1 / Phase 2 | 68 | Craig L Slingluff, JrOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
Data updated 24 days agoSource updated May 18, 2022source: clinicaltrials